Get started
Novartis AGNovartis AGNovartis AG

Novartis AG

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NVSEF chart


Full chart

Key facts today

Rapt Therapeutics has licensed its experimental allergy treatment RPT904 to Shanghai Jemincare Pharmaceutical Co, which is being developed as an alternative to Novartis' Xolair.
Analyze the impactAnalyze the impact

NVSEF upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪191.06 B‬ USD
Dividend yield (indicated)
3.81%
Price to earnings Ratio (TTM)
11.30
Basic EPS (TTM)
9.01 USD
Net income (FY)
‪15.85 B‬ USD
Revenue (FY)
‪48.50 B‬ USD
Shares float
‪1.75 B‬
Beta (1Y)
0.83

Employees


Employees (FY)
‪76.06 K‬
Change (1Y)
‪−25.65 K‬ −25.22%
Revenue / Employee (1Y)
‪637.69 K‬ USD
Net income / Employee (1Y)
‪120.24 K‬ USD

About NOVARTIS N


Sector
Health Technology
CEO
Vasant Narasimhan
Headquarters
Basel
Website
novartis.com
Founded
1996
ISIN
CH0012005267
FIGI
BBG000KSD796
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NVSEF news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NVSEF highest yielding bonds


N
US66989HAS7
NOVARTIS CAP 20/50
Yield to maturity
6.64%
Maturity date
Aug 14, 2050
N
XPND
NOVARTIS CAPITAL 15/45
Yield to maturity
5.94%
Maturity date
Nov 20, 2045
N
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.92%
Maturity date
Sep 21, 2042
N
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.79%
Maturity date
Sep 18, 2054
N
US66989HAH1
NOVARTIS CAPITAL 14/44
Yield to maturity
5.77%
Maturity date
May 6, 2044
N
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
5.30%
Maturity date
Sep 18, 2034
N
US66989HAR9
NOVARTIS CAP 20/30
Yield to maturity
5.11%
Maturity date
Aug 14, 2030
N
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031
Yield to maturity
4.98%
Maturity date
Sep 18, 2031
N
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029
Yield to maturity
4.82%
Maturity date
Sep 18, 2029
N
US66989HAN8
NOVARTIS CAPITAL 17/27
Yield to maturity
4.68%
Maturity date
May 17, 2027
N
US66989HAP3
NOVARTIS CAP 20/25
Yield to maturity
4.59%
Maturity date
Feb 14, 2025

Explore more bonds 

Sparks


Curated watchlists where NVSEF is featured.

See all sparks 

Frequently Asked Questions


The current price of NVSEF is 95.49 USD — it has decreased by −0.64% in the past 24 hours. Watch Novartis AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Novartis AG stocks are traded under the ticker NVSEF.
NVSEF stock has fallen by −3.42% compared to the previous week, the month change is a −7.55% fall, over the last year Novartis AG has showed a −2.74% decrease.
We've gathered analysts' opinions on Novartis AG future price: according to them, NVSEF price has a max estimate of 137.33 USD and a min estimate of 93.08 USD. Watch NVSEF chart and read a more detailed Novartis AG stock forecast: see what analysts think of Novartis AG and suggest that you do with its stocks.
NVSEF reached its all-time high on Sep 3, 2024 with the price of 123.55 USD, and its all-time low was 34.25 USD and was reached on Mar 10, 2009. View more price dynamics on NVSEF chart.
See other stocks reaching their highest and lowest prices.
NVSEF stock is 0.83% volatile and has beta coefficient of 0.83. Track Novartis AG stock price on the chart and check out the list of the most volatile stocks — is Novartis AG there?
Today Novartis AG has the market capitalization of ‪189.86 B‬, it has decreased by −0.07% over the last week.
Yes, you can track Novartis AG financials in yearly and quarterly reports right on TradingView.
Novartis AG is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
NVSEF earnings for the last quarter are 2.06 USD per share, whereas the estimation was 1.94 USD resulting in a 6.27% surprise. The estimated earnings for the next quarter are 1.82 USD per share. See more details about Novartis AG earnings.
Novartis AG revenue for the last quarter amounts to ‪12.82 B‬ USD, despite the estimated figure of ‪12.79 B‬ USD. In the next quarter, revenue is expected to reach ‪12.99 B‬ USD.
NVSEF net income for the last quarter is ‪3.26 B‬ USD, while the quarter before that showed ‪3.27 B‬ USD of net income which accounts for −0.16% change. Track more Novartis AG financial stats to get the full picture.
Yes, NVSEF dividends are paid annually. The last dividend per share was 3.76 USD. As of today, Dividend Yield (TTM)% is 3.81%. Tracking Novartis AG dividends might help you take more informed decisions.
Novartis AG dividend yield was 3.89% in 2023, and payout ratio reached 51.36%. The year before the numbers were 3.83% and 105.08% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 23, 2024, the company has ‪76.06 K‬ employees. See our rating of the largest employees — is Novartis AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novartis AG EBITDA is ‪21.26 B‬ USD, and current EBITDA margin is 44.33%. See more stats in Novartis AG financial statements.
Like other stocks, NVSEF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novartis AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novartis AG technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novartis AG stock shows the sell signal. See more of Novartis AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.